Ultima Vez Modificado: 9 de septiembre del 2007
Dear OncoLink "Ask The Experts,"
I had a mastectomy at age 36. The pathology report indicated the presence of both DCIS and LCIS. No lymph node involvement was seen and the estrogen receptor status was negative, so I had no further treatment.
Recently, at age 49, I was diagnosed with invasive ductal cancer of my other remaining breast and had a second mastectomy. There was no lymph node involvement, but this cancer was estrogen receptor positive. My oncologist recommends I take Tamoxifen as I am premenopausal. I read that Tamoxifen helps prevent recurrent breast cancer, but how would this benefit me, since I have already had both breasts removed and no lymph node involvement?
Carolyn Vachani RN, MSN, AOCN, OncoLink's Nurse Educator, responds:
It sounds like you already know that Tamoxifen decreases the chances of developing a new breast cancer, recurrence of an old breast cancer, or spread of cancer to distant sites (i.e. metastatic cancer). Even thought your breast tissue has been removed, cancer can still recur in that area or in other locations. For example, we can see it reappear along the surgical scar line (called a chest wall recurrence) or in another area (bone, liver, lung, etc).
Even when we think all of the cancer cells are gone, there may be stray cells that we cannot see on scans or exams. We know this because research has shown that without further treatment after surgery (i.e. chemotherapy, hormone therapy or radiation therapy), some cancers will return. We can't yet predict exactly which cancers will recur and which will not, but Tamoxifen is one way to help eliminate those stray cells and prevent the cancer from returning.Imprima English
Jan 6, 2011 - The U.S. Food and Drug Administration announced today that certain tobacco products, including cigarettes, roll-your-own tobacco, and all smokeless products, introduced or changed in the United States after Feb. 15, 2007, must be reviewed by the agency. In its newly published guidance, the agency says that any company marketing a tobacco product must prove that the product is "substantially equivalent" to products commercially available on Feb. 15, 2007.
Jan 6, 2011
May 3, 2011
Sep 21, 2010